Last updated on March 2019

A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RETREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER


Brief description of study

To determine the safety and tolerability of initial treatment and re-treatment(s) with SAGE-217 in adults with Major Depressive Disorder (MDD) currently experiencing a major depressive episode (MDE) over a 1-year period

Clinical Study Identifier: TX218071

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.